Search results
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat...
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks via Yahoo Finance· 7 months agoImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong...
ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug...
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx,...
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop...
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for...
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the...
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks via Yahoo Finance· 10 months agoImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings...
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
Benzinga via Yahoo Finance· 1 year agoImmunoGen Inc (NASDAQ: IMGN) announced a global, multi-target license and option agreement that...
With 72% institutional ownership, ImmunoGen, Inc. (NASDAQ:IMGN) is a favorite amongst the big guns
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in ImmunoGen, Inc. (NASDAQ:IMGN) should be aware of the most powerful shareholder...